Welcome to another edition of CEDARS/ASPENS Debates. CEDARS/ASPENS is a society of cornea, cataract and refractive surgery specialists, here to discuss some of the latest hot topics in ophthalmology.
While drops are still a large part of early treatment for glaucoma and ocular hypertension, selective laser trabeculoplasty is on the rise. In 2019, the 3-year results of the Laser in Glaucoma and Ocular Hypertension (LiGHT) trial, published in The Lancet, showed SLT to be clinically more successful and more cost-effective than IOP-lowering drops as a primary treatment for both these conditions,